Myostatin plays a negative role in skeletal muscle growth regulation but its potential 17 role in the ovary has received little attention. Here, we first examined relative 18 expression of myostatin (MSTN), myostatin receptors (ACVR1B, ACVR2B and 19 TGFBR1) and binding protein, follistatin (FST), in granulosa (GC) and theca (TC) cells 20 of developing bovine follicles. Secondly, using primary GC and TC cultures, we 21 investigated whether myostatin affects steroidogenesis and cell number. Thirdly, effects 22 of gonadotropins and other intrafollicular factors on MSTN expression in GC and TC 23 were examined. MSTN, ACVR1B, TGFBR1, ACVR2B and FST mRNA was detected 24 in both GC and TC at all follicle stages. Immunohistochemistry confirmed follicular 25 expression of myostatin protein. Interestingly, MSTN mRNA expression was lowest in 26 GC of large estrogen-active follicles while GC FST expression was maximal at this 27 stage. In GC, myostatin increased basal CYP19A1 expression and estradiol secretion 28 whilst decreasing basal and FSH-induced HSD3B1 expression and progesterone 29 secretion and increasing cell number. Myostatin also reduced IGF-induced progesterone 30
Introduction 40
Ovarian follicle development is dependent on the actions and interactions of systemic 41 and intra-ovarian regulatory signals. Whilst pituitary gonadotrophins (FSH, LH) are the 42 key endocrine signals driving follicle development, a complex array of locally-produced 43 growth factors also contribute to the modulation of follicular somatic cell proliferation 44 and differentiation, 'initial' and 'cyclic' follicle recruitment, steroidogenesis, dominant 45 follicle selection and ovulation (Campbell et al. 2003 , Webb et al. 2003 . Prominent 46 amongst these are various members of the transforming growth factor-β (TGF-β) 47 superfamily including growth and differentiation factor-9 (GDF9), anti-mullerian 48 hormone (AMH), inhibins, activins and several bone morphogenetic proteins (BMP) 49
including BMP2, BMP4, BMP6 and BMP7 (Shimasaki et al. 2004 , Knight & Glister 50 2006 ). In the present study we examined the potential involvement of another TGF-β 51 superfamily member, myostatin (also known as GDF8) in regulating ovarian follicle 52
function. 53
Myostatin is well-recognised for its negative autocrine/paracrine role in skeletal muscle 54 development (Otto & Patel 2010 , Schiaffino et al. 2013 ). Myostatin-null mice show a 55 pronounced increase in muscle mass due to muscle fibre hyperplasia and hypertrophy 56 Myostatin signals through the activin receptor type 2B (ACTR2B), forming a signalling 69 complex with ACVR1B (ALK4) and/or TGFBR1(ALK5) that activates an intracellular 70 Smad 2/3-dependent signal transduction pathway. Myostatin receptor activation can 71 also signal in a Smad-independent manner via activation of MAPK and inhibition of 72
Akt pathways (Rebbapragada et al. 2003) . Binding of myostatin to its signalling 73 receptors is modulated by follistatin (Amthor et al. 2004) . Follistatin was initially 74 identified as a secreted activin-binding protein but has since been shown to bind several 75 resembling that of myostatin-null mice (Lee & McPherron 2001) . 80
Global microarray studies of the bovine ovary revealed that myostatin mRNA is 81 expressed in follicular granulosa (Skinner et al. 2008 Given the paucity of information on the ovarian expression and possible intraovarian 97 role(s) of myostatin, particularly in relation to actions on non-luteinized follicular cells, 98 the aims of the present study were to: (1) examine mRNA expression profiles for 99 myostatin, its signalling receptors and binding protein (follistatin; FST) in granulosa 100 (GC) and theca (TC) cells across different stages of bovine antral follicle development; 101
(2) use non-luteinized bovine GC and TC culture models to investigate whether 102 myostatin affects steroid production; (3) determine whether the effect of myostatin can 103 be attenuated by follistatin; (4) investigate whether thecal and granulosal expression of 104 myostatin mRNA is modulated by gonadotropins and several intrafollicular factors 105 implicated in the regulation of follicular steroidogenesis. 106 107 Briefly, antral follicles of diameter 3-18mm were dissected out and sorted by size into 116 small (3-6mm; n = 30), medium (7-10mm; n = 43) and large (11-18mm; n = 37) 117 categories. For each follicle GC and TC layers were retrieved for RNA extraction and 118 follicular fluid recovered for steroid hormone analysis. Follicles in the large (11-18mm) 119 category were subdivided retrospectively into large estrogen-active (LEA; E:P ratio >1) 120 and large estrogen-inactive (LEI; E:P ratio <1) categories according to their 121 intrafollicular ratio of estrogen to progesterone (E:P ratio). Isolated GC and TC were 122 homogenised in 0.5ml of Tri reagent (Sigma UK Ltd, Poole) and stored at -80 0 C for 123 subsequent RNA purification. The number of GC and TC RNA extracts recruited to the 124 study (n = 82 GC samples; n = 87 TC samples; see fig. 1 for n-values for individual 125 follicle categories) was lower than the number of extracts processed because samples 126 indicating >5% GC/TC cross contamination were rejected during an initial quality 127 control screen. This involved a RT-qPCR-based comparison of relative transcript 128 abundance of four GC/TC-specific 'marker' transcripts (FSHR and CYP19A1 for GC, 129 (v/v) antibiotic-antimycotic solution, 10 ng/ml bovine insulin, 2 mM L-glutamine, 10 141 mM Hepes, 5 µg/ml apotransferrin, 5 ng/ml sodium selenite, 0.1% BSA. In the case of 142 GC cultures, media was also supplemented with 10 -7 M androstenedione as aromatase 143 substrate (all media and supplements were purchased from Sigma). Media were 144 replenished and treatments added on days 2 and 4 (see below). Cultures were terminated 145 on day 7 when conditioned media were retained for hormone assays and viable cell 146 number was determined by neutral red uptake assay as described elsewhere ( 
Effect of myostatin on granulosal expression of steroidogenic pathway components 172
To evaluate the effects of myostatin on expression of key transcripts involved in 173 steroidogenesis (CYP11A1, HSD3B1, CYP19A1, FSHR) GC were cultured in 24-well 174 plates (250,000 cells/well) and exposed to fixed concentrations of myostatin (100 175 ng/ml) in the presence and absence of an optimal concentration of FSH (300 pg/ml). At 176 the end of culture, media were removed and cell lysates were prepared for total RNA 177 extraction and RT-qPCR analysis. 178 respectively. The androstenedione ELISA had a detection limit of 30 pg/ml and intra-223 and inter-assay CVs were 7% and 10% respectively. The estradiol ELISA had a 224 detection limit of 15 pg/ml and intra-and inter-assay CVs were 6% and 9% respectively. 225
Do gonadotropins and other factors modulate MSTN expression by cultured GC and 180

Immunohistochemistry 227
Bovine ovaries were dissected into segments and fixed in formalin for 48 hours, before 228 being dehydrated through an alcohol series, embedded in wax and sectioned (5µm) onto FST mRNA expression was found in both TC and GC at all stages of follicle 272 development examined with much higher expression levels in GC than TC (Fig. 1B) . 273
Interestingly, the expression of FST in GC sharply increased in LEA follicles but 274 remained low in LEI follicles; this was opposite to what was observed for MSTN. 275
Myostatin receptors (ACVR2B, ACVR1B and TGFBR1) 276
ACVR1B, TGFBR1 and ACVR2B mRNA expression was found in both TC and GC at 277 all stages of follicle development examined. The expression of ACVR2B and ACVR1B 278 was generally higher in GC than TC while TGFBR1 expression levels were broadly 279 similar in the two cell types. No notable changes in cell-specific patterns of expression 280 of these receptors between each stages of follicle development were evident ( Fig.  281 1C,D,E respectively). 282 283
Effect of myostatin on basal and FSH-induced steroid secretion by GC 284
Myostatin promoted a marked increase in basal estradiol secretion by cultured GC (~12-285 fold; P<0.0001; Fig. 3A ) but did not modulate the >30-fold increase in estradiol 286 secretion elicited by FSH. Myostatin suppressed both basal (P<0.01) and FSH-induced 287 (P<0.001) progesterone secretion (Fig. 3B ). In addition, myostatin promoted a modest 288 though significant increase in cell number under basal conditions (~20% increase; 289 P<0.001), but not under FSH-stimulated conditions (Fig. 3C) . 290 291
Effects of myostatin on GC expression of steroidogenesis-related transcripts 292
The stimulatory action of myostatin on basal estradiol secretion was accompanied by a 293 ~10-fold increase in CYP19A1 expression level (P<0.05; Fig. 3D ). Concomitantly, a 294 reduction in CYP11A1 and HSD3B1 expression level was observed (P<0. 05; Fig. 3EF ) 295 that mirrored the myostatin-induced decrease in progesterone secretion. Myostatin did 296 not affect FSHR expression (data not shown). 
Effects of myostatin on thecal steroid secretion and viable cell number 318
Myostatin suppressed androstenedione secretion in a dose-dependent manner (P<0.001) 319
with an IC 50 of ~10 ng/ml under LH-stimulated conditions (Fig. 6A ). No effect of 320 myostatin on progesterone secretion was observed (Fig. 6B ). Viable cell number was 321 increased (~25%; P<0.0001) by myostatin under both basal and LH-stimulated 322 conditions ( Fig. 6C ). LH increased both androstenedione and progesterone secretion but 323 did not affect viable cell number. 324
Can follistatin neutralize the effect of myostatin on androstenedione secretion? 325
Treatment of cells with myostatin alone decreased androstenedione secretion by ~80% 326 (P<0.000; Fig. 7 ). Co-treatment with follistatin partially reversed this inhibitory action 327 (P<0.001). Treatment with follistatin alone tended to increase androstenedione secretion 328 but the effect was not statistically significant. 329 330 responsiveness to FSH, providing a potential mechanism for selecting the dominant 386 follicle from the cyclically-recruited growing cohort (Campbell et al. 1995 , Webb et al. 387 2003 . It was therefore pertinent to investigate whether myostatin affected the GC 388 response to IGF-1 treatment. Although the results showed no effect on IGF-induced 389 estradiol production or cell number, myostatin increased basal estradiol production and 390 cell number whilst reducing basal and IGF-induced progesterone production. As such, 391 these observations further support the notion that myostatin has a role to delay 392 premature follicle maturation and luteinisation. to place these in a physiological context. 449
Effects of LH and BMP6 on MSTN mRNA expression by cultured TC 331
With respect to myostatin-null mice, there are few, if any, references to their ovarian 450 phenotype and the potential impact of the mutation on gonadal function and fertility is 451 unknown to us. However, an in vivo study involving active immunization of female 452 mice against myostatin, showed that the number of developing ovarian follicles in their 453 female progeny was ~50% lower than that of control mice, with a similar diminution in 454 litter size (Liang et al. 2007 ). Double-muscled cattle with myostatin mutations, 455 reportedly show delayed puberty, reduced female fertility and a higher incidence of 456 dystocia and perinatal calf mortality/morbidity is associated with the large size of calves 457 ). However, we are not aware of any studies examining whether 458 perturbations in ovarian follicle dynamics or steroidogenesis occur in double-muscled 459 cattle. Whilst information is currently lacking on the above, it is possible that the 460 physiological actions of myostatin in the ovary are functionally redundant owing to 461 compensatory effects of other TGF-β ligands (e.g activins) that can signal via the same, 462 or overlapping, receptors to elicit similar regulatory actions on theca and granulosa cells. 463
In summary, this study provides novel information on the expression of myostatin, its 464 signalling receptors and the binding protein, follistatin, in theca and granulosa cells of 465 developing bovine antral follicles. Myostatin expression in GC declined to a very low 466 level in large estrogen-active follicles in which expression of follistatin was maximal, 467
suggesting attenuation of GC-derived myostatin signalling at this stage. Since myostatin 468 suppressed thecal androgen production in a dose-dependent manner, an effect partially 469 rescued by follistatin, it is hypothesised that attenuation of myostatin signalling in large 470 antral follicles could facilitate thecal androgen production required as a substrate for 471 granulosal aromatase enzyme and estrogen synthesis. Paradoxically, however, 472 myostatin was found to promote CYP19A1 expression and estradiol production by 473 granulosa cells under 'basal' conditions whilst suppressing CYP11A1 and HSD3B1 474 expression and progesterone production (see Fig. 9 ). Taken together, this suggests a role 475 for myostatin in delaying follicle progression towards pre-ovulatory maturation and 476 luteinisation, in a manner similar to that suggested for granulosa-derived activin 477 including whole animal models, are required to confirm and extend these in vitro 479 observations based on bovine ovarian cell culture models. It is also speculated that 480 muscle-derived myostatin conveyed to the ovary via the systemic circulation may 481 contribute to the regulation of follicle function. In a similar manner, testicular 482 steroidogenesis and gametogenesis may be influenced by circulating and/or locally-483 produced myostatin although we are not aware of any studies, to date, examining this 484 possibility. 485 486
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